Sohini Das, Sundar Sethuraman

Stories by Sohini Das, Sundar Sethuraman

Broking industry adds 4mn A/Cs for 3rd month

Broking industry adds 4mn A/Cs for 3rd month

Rediff.com   6 Mar 2024

For the third month running, investors opened over four million new demat accounts in February, showing growing household confidence in stock markets and their increased risk appetite. Over 13.12 million new demat accounts have been opened in the last three months, taking the total count close to the 150-million mark. Demat accounts are needed for trading and holding shares electronically.

Fundraising via QIPs gain traction as India Inc looks for growth capital

Fundraising via QIPs gain traction as India Inc looks for growth capital

Rediff.com   5 Mar 2024

Equity fundraising through qualified institutional placements (QIPs) has gained traction, thanks to supportive equity markets and the need for fresh fundraising to meet capital expenditure (capex) requirements.

Skoda to drive in Brezza, Sonet rival in H1FY25

Skoda to drive in Brezza, Sonet rival in H1FY25

Rediff.com   28 Feb 2024

koda Auto India is set to drive in a new car by the first half of next year to reach its target of 100,000 unit annual sales in the country by 2026. The compact sports utility vehicle (SUV) will be positioned against the likes of Maruti Brezza, Hyundai Venue, and Kia Sonet, and would be competitively priced, a senior company official said. koda will also export the car to right-hand-drive markets like Australia, New Zealand and the Asean nations.

India-listed multinational arms outclass parent firms' valuations

India-listed multinational arms outclass parent firms' valuations

Rediff.com   28 Feb 2024

It's not only the Indian markets that command a valuation premium over their global peers; shares of subsidiaries of India-listed multinational companies (MNCs) also trade at rich valuations compared to their parent companies. An analysis of 12-month forward price-to-earnings (P/E) and price-to-book (P/B) multiples of domestically listed MNCs shows that most quotes have a premium ranging from 2.1x to 6x that of their parent. Similarly, P/B, in most cases, is significantly higher in the domestic market.

'The formulations business been a growth driver'

'The formulations business been a growth driver'

Rediff.com   24 Feb 2024

'However, we have seen weakness in our active pharmaceutical ingredients business.'

'In an election year, markets flourish'

'In an election year, markets flourish'

Rediff.com   23 Feb 2024

'Historically, the markets tend to perform well during election years as governments aim to increase spending and call attention to growth.'

Tax poser in the way of Hyundai local arm listing

Tax poser in the way of Hyundai local arm listing

Rediff.com   15 Feb 2024

South Korean auto giant Hyundai Motor Company is considering tax implications of listing its Indian unit before taking a final call, according to sources privy to the development. Hyundai Motor is mulling an initial public offering (IPO) for its Indian arm to raise around $3 billion (at a valuation of up to $30 billion), and talks are in the early stages between the company and bankers, banking sources revealed. Hyundai Motor India Ltd (HMIL), however, declined to comment on the development.

Rooftop solar charges up electric vehicle boom in India's smaller cities

Rooftop solar charges up electric vehicle boom in India's smaller cities

Rediff.com   12 Feb 2024

The push given to rooftop solar installation in the Interim Budget ties in with its high rate of adoption in Tier-II and -III cities of India. If original equipment manufacturers (OEMs) in the automobile industry, government, and the solar sector are to be believed, in cities of Rajasthan, Gujarat, and Kerala, 45-50 per cent of electric-vehicle (EV) users are employing rooftop power to charge their vehicles. This is compared to the national average of 25 per cent, say industry sources.

GOOD News! No Drug Price Hike In 2024

GOOD News! No Drug Price Hike In 2024

Rediff.com   6 Feb 2024

For the consumer, there would be practically no impact on prices of essential medicines this year.

Q3 result preview: US, India to aid revenue growth for Pharma Inc

Q3 result preview: US, India to aid revenue growth for Pharma Inc

Rediff.com   30 Jan 2024

The pharmaceuticals sector is expected to post a revenue growth of around 13.5 per cent and a net profit growth of 30.3 per cent for the third quarter of 2023-24 (FY24), riding on the approval for niche drugs in the US market, fall in raw material prices and correction in shipping rates. In the healthcare segment, hospitals are expected to post revenue growth of 13 per cent during the coverage, while net profit growth would be around 37 per cent, ICICI Securities said in a note. However, the performance may not be comparable on a sequential basis due to the offset of the festive season in Q3FY24, the analysts noted.

HDFC Bank-led FPI selloff: The fifth-highest weekly exit since 2008

HDFC Bank-led FPI selloff: The fifth-highest weekly exit since 2008

Rediff.com   30 Jan 2024

Foreign portfolio investors (FPIs) sold shares worth Rs 20,170 crore ($2.4 billion) recently. This marked the fifth-highest weekly outflow from overseas funds since the beginning of 2008 and the largest since the last week of March 2020. Due to the Covid scare, FPIs had sold shares worth Rs 21,951 crore during that week, causing the market to decline by nearly 20 per cent.

How AI Is Transforming Auto Manufacturing

How AI Is Transforming Auto Manufacturing

Rediff.com   30 Jan 2024

'From data on enquiries, we can build what we call a data lake or a data warehouse where data is classified into various cohorts and then we use AI and ML tools to predict demand down the line.'

'Aster DM's plan is to be among top three in India'

'Aster DM's plan is to be among top three in India'

Rediff.com   27 Jan 2024

'Now that we are a pure-play India business, many investors are open to investing.'

Fortis plans acquisitions, may opt for neutral brand name

Fortis plans acquisitions, may opt for neutral brand name

Rediff.com   22 Jan 2024

Delhi-headquartered Fortis Healthcare is open to acquisition of hospitals with over 250-300 bed sizes as part of its strategy to grow at a faster clip. It may also opt for a neutral brand name soon. Neutral brand is a new brand, which is not owned by any of the stakeholders.

Delivery-based trades drop amid valuation concerns

Delivery-based trades drop amid valuation concerns

Rediff.com   22 Jan 2024

Investors are reluctant to take long-term positions this year after the spectacular gains in 2023. The delivery-based trades on the National Stock Exchange (NSE) have declined to below 36 per cent this year from an average of 38.1 per cent in 2023. Investors tend to seek delivery for stocks where they see a long-term investment opportunity or tactical positional trade.

Domestic pharma market grew by 6.8% in 2023

Domestic pharma market grew by 6.8% in 2023

Rediff.com   22 Jan 2024

The Indian pharmaceutical market (IPM) grew 6.8 per cent to touch a turnover of ~1.93 trillion in calendar year 2023, despite volumes going down marginally by 0.9 per cent. This indicates the price increase has been the major growth driver. Growth in the moving annual turnover (the previous 12 months' turnover) in December was 5.1 per cent and that in new product introduction 2.6 per cent, while volumes dipped 0.9 per cent, leading to an overall growth rate of 6.8 per cent, according to the data from market research firm Pharmatrac.

Record buyback of Rs 47,810 cr by 48 firms in 2023, highest in 6 yrs

Record buyback of Rs 47,810 cr by 48 firms in 2023, highest in 6 yrs

Rediff.com   13 Jan 2024

As much as Rs 47,810 crore was spent on share buybacks by 48 companies in 2023 -- the highest amount since 2017. This surge in value was largely driven by a few large-sized issues, including those by Tata Consultancy Services (Rs 17,000 crore), Larsen & Toubro (Rs 10,000 crore), and Wipro (Rs 12,000 crore). In 2022, 58 companies had repurchased shares worth Rs 38,305 crore, according to data from Prime Database.

A fourth of FPI inflows in 2023 went into primary markets, shows data

A fourth of FPI inflows in 2023 went into primary markets, shows data

Rediff.com   11 Jan 2024

Foreign portfolio investors (FPIs) pumped in Rs 1.7 trillion into domestic stocks in 2023, one of the highest net inflows ever witnessed during a calendar year, of which 25 per cent went into the direct buying of stocks. Data provided by depository NSDL revealed that Rs 44,950 crore of the total FPI flows last year went into primary issuances. A large portion of the FPI investments through the stock exchange route went into block deals, thereby reducing the actual investments made via direct buying of stocks. Last year saw selldowns or block deals worth Rs 2 trillion.

From Ashok Leyland to VECV, busmakers' sales entered the fast lane in 2023

From Ashok Leyland to VECV, busmakers' sales entered the fast lane in 2023

Rediff.com   10 Jan 2024

The demand for buses largely remained robust in 2023, driven by the increasing need for public mobility and replacement. Ashok Leyland Limited (ALL) recorded a 64 per cent year-on-year increase in sales of medium and heavy commercial vehicle (MHCV) buses during the April-to-December period of 2023 to 11,216 units. Volvo Eicher Commercial Vehicles (VECV) posted 24.7 per cent sales growth between April and December for light and medium-duty buses, and 36.9 per cent growth for heavy-duty buses.

'APIs are a very strategic part of Biocon's business'

'APIs are a very strategic part of Biocon's business'

Rediff.com   7 Jan 2024

'There is no reason why we should break this business up.'